The short version
- Singapore’s medical regulator has authorized HistoSonics’ Edison system, which breaks up liver tumors with pulses of focused ultrasound instead of heat or a blade.
- A 2026 review of 10 studies and 553 patients found the treatment hit its target 94% of the time, with serious complications in about 7%.
- No trial has compared histotripsy head to head with other tumor treatments, and long-term follow-up is still short.
Singapore’s Health Sciences Authority has authorized HistoSonics’ Edison Histotripsy System for destroying liver tumors, the company announced on November 2. Histotripsy aims pulses of focused ultrasound through the skin to break up and liquefy the tumor tissue mechanically. The company describes it as working “without incisions, radiation, or thermal energy.” The FDA cleared it for liver tumors in October 2023. This year brought Taiwan in May and a European CE mark in July, and in May the company asked the FDA to add kidney tumors, based on a 67-patient single-arm trial, #HOPE4KIDNEY, whose results have not been published.
The best summary of the liver evidence is a meta-analysis in EClinicalMedicine in April, led by Chase Wehrle at the Cleveland Clinic. Across 10 studies and 553 patients, the treatment reached its target in 94.1% of cases. Four of the studies reported serious complications, at a pooled rate of 7.0%, with a wide margin of uncertainty. The authors call the results promising but warn that the studies are few, measure control differently and follow patients only briefly.
It is spreading quickly through regulators. The randomized comparison with other ablation methods has not been done.



